Bicyclic urea kinase inhibitors and uses thereof

US12398145B2 · kind B2 · utility

Assignees

• The Broad Institute, Inc. · US
• The General Hospital Corporation · US
• DANA-FARBER CANCER INSTITUTE, INC. · US

Inventors

• Nathanael S. Gray · Boston, US
• Yanke Liang · Belmont, US
• Hwan Geun Choi · Seoul, KR
• Thomas Sundberg · Boston, US
• Alykhan Shamji · Somerville, US
• Ramnik Xavier · Brookline, US
• David E. Fisher · Newton, US
• Nisma Mujahid · Spencerport, US

Key dates

• Filing date: Mar 27, 2023
• Grant date: Aug 26, 2025
• Expiry date: Apr 13, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.